Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes
- PMID: 8803956
Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes
Abstract
Phosphodiesterase (PDE) isoenzyme type IV is the predominant cyclic AMP hydrolytic activity in polymorphonuclear leukocytes (PMNs). PDE IV inhibitors depress functional responses of PMNs but their influence on intracellular calcium concentration ([Ca2+]i) has not been extensively studied. The present study examined the effects of rolipram (a selective PDE IV inhibitor) on the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP)-induced changes of [Ca2+]i in fura-2 loaded human PMNs. Rolipram (1 nM-10 microM) did not alter basal [Ca2+]i values. fMLP (10 nM approximately EC50) produced a transient calcium response, i.e., a peak followed by decay to a residual value above baseline. Peak [Ca2+]i values after fMLP were not altered but a faster decay and a lower residual [Ca2+]i were observed in rolipram (0.1-10 microM)-treated cells. fMLP added after thimerosal (20 microM) produced a peak followed by a sustained oscillatory response. Rolipram (up to 10 microM) did not alter the peak but inhibited the sustained response (-log IC50 = 6.39 +/- 0.12). The inhibitory effects of rolipram may be due to alterations in the mobilization of Ca2+ produced by the increase in the cellular content of cyclic AMP. SKF94120 (a selective PDE III inhibitor) produced minor effects on the fMLP-induced calcium response. SCA40 (a mixed PDE III/IV/V inhibitor) produced similar effects but was less potent than rolipram. Reduction of the calcium response probably underlies the inhibition of PMN functions produced by PDE IV inhibitors.
Similar articles
-
Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.Br J Pharmacol. 1996 Sep;119(1):99-106. doi: 10.1111/j.1476-5381.1996.tb15682.x. Br J Pharmacol. 1996. PMID: 8872362 Free PMC article.
-
Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.J Cereb Blood Flow Metab. 1997 Feb;17(2):210-9. doi: 10.1097/00004647-199702000-00011. J Cereb Blood Flow Metab. 1997. PMID: 9040501
-
Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils.Br J Pharmacol. 1998 Jun;124(3):547-55. doi: 10.1038/sj.bjp.0701849. Br J Pharmacol. 1998. PMID: 9647480 Free PMC article.
-
Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.Agents Actions Suppl. 1991;34:379-402. Agents Actions Suppl. 1991. PMID: 1665311 Review.
-
Biochemical characteristics and cellular regulation of phosphodiesterase IV.Agents Actions Suppl. 1993;43:51-71. doi: 10.1007/978-3-0348-7324-6_5. Agents Actions Suppl. 1993. PMID: 8396319 Review.
Cited by
-
The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.Br J Pharmacol. 1999 Feb;126(4):979-88. doi: 10.1038/sj.bjp.0702387. Br J Pharmacol. 1999. PMID: 10193778 Free PMC article.
-
Anti-oxidative effects of theophylline on human neutrophils involve cyclic nucleotides and protein kinase A.Inflammation. 1998 Dec;22(6):545-57. doi: 10.1023/a:1022306328960. Inflammation. 1998. PMID: 9824770
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous